We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    467-712
Previous Study | Return to List | Next Study

Long-term Use of Takepron Capsules on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Low-dose Aspirin

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02099682
First Posted: March 31, 2014
Last Update Posted: November 4, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Takeda
  Purpose
The purpose of this study is to investigate the safety and efficacy of long-term administration of lansoprazole (Takepron) for up to 12 months in the routine clinical setting in patients receiving low-dose aspirin

Condition Intervention
Gastric or Duodenal Ulcers Drug: Lansoprazole

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Takepron Capsules 15/ Orally Dispersing (OD) Tablets 15 Special Drug Use Surveillance Long-term Use Survey on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Low-dose Aspirin

Resource links provided by NLM:


Further study details as provided by Takeda:

Primary Outcome Measures:
  • Frequency of Adverse Drug Reactions [ Time Frame: 12 months ]
    Frequency, severity, and time to onset of adverse drug reactions tabulated by each symptom. Adverse events are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product reported from the first dose of study drug to the last dose of study drug. Among these, events which are considered possibly associated with a medicinal product are defined as adverse drug reactions.


Secondary Outcome Measures:
  • Presence or Absence of Endoscopic Examinations [ Time Frame: From baseline to 12 months ]
    Summary of data on the presence or absence of endoscopic examinations.

  • Presence of Gastric or Duodenal Ulcer [ Time Frame: From baseline to 12 months ]
    Summary of data on the presence or absence of gastric or duodenal ulcers.

  • Presence of Gastric or Duodenal Hemorrhagic Lesion [ Time Frame: From baseline to 12 months ]
    Summary of data on the presence or absence of gastric or duodenal hemorrhagic lesions.

  • Presence of Either Gastric/Duodenal Ulcer, or Gastric/Duodenal Hemorrhagic Lesion [ Time Frame: From baseline to 12 months ]
    Summary of data on the presence or absence of gastric/duodenal ulcer gastric/duodenal hemorrhagic lesion.

  • Treatment for Gastric/Duodenal Ulcer or Lesion [ Time Frame: From baseline to 12 months ]
    Summary of data on the presence or absence of treatment for duodenal ulcers or hemorrhagic lesions.

  • Details of Treatment (Including Duplicates) for Gastric or Duodenal Ulcers or Hemorrhagic Lesions [ Time Frame: From baseline to 12 months ]
    Summary of data on the details of treatment for gastric or duodenal ulcers or hemorrhagic lesions.

  • Treatment Outcome (Including Duplicates) for Gastric or Duodenal Ulcers or Hemorrhagic Lesions [ Time Frame: From baseline to 12 months ]
    Summary of data on the outcome of treatment for gastric or duodenal ulcers or hemorrhagic lesions.


Enrollment: 3366
Study Start Date: August 2010
Study Completion Date: January 2014
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Lansoprazole 15 mg
Lansoprazole 15 mg orally once daily
Drug: Lansoprazole
Lansoprazole Capsules 15/ OD Tablets
Other Name: Takepron Capsules 15/ OD Tablets

Detailed Description:

This is a special survey on long-term use (for up to 12 months) of lansoprazole (Takepron) to determine the incidence of adverse drug reactions in the routine clinical setting in patients receiving low-dose aspirin.

The usual adult dosage is 15 mg of lansoprazole administered orally once daily.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Gastric or duodenal ulcers
Criteria

Inclusion Criteria:

  • (1) Patients with a history of gastric or duodenal ulcers (2) Patients requiring long-term use of low-dose aspirin (81-324 mg once daily) as prophylaxis for thromboembolism (3) Patients taking low-dose oral aspirin (81-324 mg once daily) at the start of administration of lansoprazole (including patients who start low-dose aspirin on the same day as the start of administration of lansoprazole)

Exclusion Criteria:

  • (1) Patients with gastric or duodenal ulcer (in the active [A1, A2] or healing [H1, H2] stage if assessed endoscopically) at the start of administration of lansoprazole (2) Patients with active upper gastrointestinal hemorrhage at the start of administration of lansoprazole (3) Patients with contraindications for lansoprazole
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02099682


Sponsors and Collaborators
Takeda
Investigators
Study Chair: Postmarketing Group Manager Takeda
  More Information

Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT02099682     History of Changes
Other Study ID Numbers: 467-712
JapicCTI-142414 ( Registry Identifier: JapicCTI )
JapicCTI-R150735 ( Registry Identifier: JapicCTI )
First Submitted: March 26, 2014
First Posted: March 31, 2014
Results First Submitted: June 5, 2015
Results First Posted: June 25, 2015
Last Update Posted: November 4, 2016
Last Verified: September 2016

Keywords provided by Takeda:
Pharmacological therapy

Additional relevant MeSH terms:
Ulcer
Recurrence
Duodenal Ulcer
Pathologic Processes
Disease Attributes
Peptic Ulcer
Duodenal Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Stomach Diseases
Aspirin
Lansoprazole
Dexlansoprazole
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Antipyretics
Anti-Ulcer Agents